Skip to main content.

Ronny Rotondo, MDCM, FRCPC

Ronny Rotondo portrait
Associate Professor, Radiation Oncology
rrotondo@kumc.edu

Professional Background

Dr. Rotondo is an Associate Professor of Radiation Oncology and is the Medical Director of Proton therapy at the University of Kansas Health System. He also serves as the Director of the Pediatric Radiotherapy Program. He has extensive training and expertise in the management of pediatric malignancies and also specializes in the treatment of adult brain tumors, base of skull and spine tumors, and soft tissue and bone sarcomas. He is board certified in radiation oncology clinical practice in both the United States and Canada.

Prior to joining the University of Kansas Health System, he held a faculty position at the University of Florida Health Proton Therapy Institute (UFHPTI). During his tenure at UFHPTI, he was appointed as an Assistant Professor and directed the adult central nervous system tumor program as well as the skull base and spine sarcoma program, developing a unique expertise in the management of chordomas and chondrosarcomas with a national and international referral base. He was also an integral member of the pediatric radiotherapy program.

Dr. Rotondo completed his Bachelor of Science in Microbiology and Immunology at McGill University in Montreal, Canada. He remained at McGill University where he also earned his Doctorate of Medicine and completed his residency in the Department of Radiation Oncology. He subsequently completed a one-year fellowship in adult proton radiation therapy at the Massachusetts General Hospital - Harvard University and two years of dedicated fellowship training in pediatric proton radiation therapy at the University of Florida.

Education and Training
  • Other, Radiation Oncology, McGill University, Montreal, Quebec
  • BS, Microbiology and Immunology, McGill University, Montreal, Quebec
  • Clinical Fellowship, Pediatric Proton Radiation Therapy Fellowship, University of Florida Proton Therapy Institute, Jacksonville, FL
  • Post Doctoral Fellowship, Proton Radiation, Massachusetts General Hospital/ Harvard University, Boston, MA
  • Post Doctoral Fellowship, Radiation Oncology, McGill University, Montreal, Quebec
Licensure, Accreditations & Certifications
  • Kansas License, Kansas State Board of Healing Arts
  • Missouri License, Missouri State Board of Registration for the Healing Arts
  • The American Board of Radiology
Professional Affiliations
  • Quality & Safety Committee , Member, 2014 - Present
  • American Brachytherapy Society, Member, 2005 - Present
  • American Medical Association, Member, 2005 - Present
  • American Society for Therapeutic Radiology and Oncology , Member, 2005 - Present
  • Canadian Medical Association , Member, 2005 - Present

Research

Overview

Dr. Rotondo' s research interests include adult brain tumors, sarcoma, and skull base and spine tumors as well as leveraging proton therapy dosimetric advantages to improve the long-term outcomes and lessen the acute and late effects of radiotherapy in children and young adults. His work has been published in medical journals and has been presented at national and international conferences. He is a member of the American Society for Radiation Oncology (ASTRO), American Society of Clinical Oncology (ASCO), the Canadian Association of Radiation Oncology (CARO), the North American Skull Base Society (NASBS), and the Particle Therapy Cooperative Group - North America (PTCOG-NA) among others. Dr. Rotondo also serves as the Chair of the Proton Collaborative Group Pediatric Subcommittee and is a member of their CNS Subcommittee.

Publications
  • 2018. Optic Pathway Glioma . In Mahajan A and Paulino A (Eds.) Radiation Oncology for Pediatric CNS Tumors, 213-228
  • Hall, MD, Indelicato, DJ, Rotondo, RL, Bradley, JA. 2018. Proton Therapy for Pediatric Malignancies. In Merchant T and Kortmann RD (eds.), Pediatric Radiation Oncology Pediatric Oncology, 363-379
  • Mercado, CE, Holtzman, AL, Rotondo, R, Rutenberg, MS, Mendenhall, WM. 2019. A review of clinical outcomes for chordomas and chondrosarcomas. Head Neck, 536-541